By Sarah Roden Valeant Pharmaceuticals (NYSE:VRX) beat out Endo International in a battle to take over Salix Pharmaceuticals (NASDAQ:SLXP) in a deal valued …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) received another set of praises today from analyst Neil Maruoka of Canaccord Genuity in a research report released today. The report comes …
In a research report published Monday, Cantor analyst Irina Rivkind maintained a Buy rating on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and raised the price target to $214, …
